KR870005098A - 융합 단백질의 제조방법 - Google Patents

융합 단백질의 제조방법 Download PDF

Info

Publication number
KR870005098A
KR870005098A KR860009990A KR860009990A KR870005098A KR 870005098 A KR870005098 A KR 870005098A KR 860009990 A KR860009990 A KR 860009990A KR 860009990 A KR860009990 A KR 860009990A KR 870005098 A KR870005098 A KR 870005098A
Authority
KR
South Korea
Prior art keywords
fusion protein
acid sequence
host cell
amino acids
met
Prior art date
Application number
KR860009990A
Other languages
English (en)
Other versions
KR950000300B1 (ko
Inventor
하버만 파울
벡겐마이어 프리이드리히
Original Assignee
하인리히 벡커,베른하르트 베크
훽스트 아크티엔 게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하인리히 벡커,베른하르트 베크, 훽스트 아크티엔 게젤샤프트 filed Critical 하인리히 벡커,베른하르트 베크
Publication of KR870005098A publication Critical patent/KR870005098A/ko
Application granted granted Critical
Publication of KR950000300B1 publication Critical patent/KR950000300B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

내용 없음

Description

융합 단백질의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도 및 제1a도는 히루딘(hirudin)서열을 갖는 융합단백질을 코드화하는 플라스미드 pK 360의 합성에 관한 것이다.
제3도 및 제3a내지 3c도는 원숭이 프로인슐린(proinsulin)의 아미노산 서열을 함유하는 융합 단백질을 코드화 하는 폴리스미드 pPH 15,16,20 및 30의 작제에 관한 것이다.
제5도 및 제5a도는 히루딘의 아미노산 서열을 갖는 융합단백질을 코드화하는 플라스미드 pK 370의 작제에 관한 것이다.

Claims (8)

  1. 인터로이킨-2(IL-2)의 첫번째 100개의 아미노산에 거의 상응하는 C- 또는 N-말단 절편을 코드화하는 유전자를 숙주세포에서 발현시킴을 특징으로 하여, 융합 단백직을 제조하는 방법.
  2. 제1항에 있어서, 유전자가 하기 일반식(Ia) 또는 (Ib)의 융합단백질을 코드화 하는 방법.
    Met-X-Y-Z (Ia)
    Met-Z-Y-X (Ib)
    상기식에서, X는 주로 인간의 인터로 이킨-2의 대략 첫번째 100개의 아미노산의 아미도산 서열을 나타내고, Y는 직접 결합을 나타내거나, 유전적으로 코드화 가능한 아미노산으로 이루어지고 아미노산 서열 Z가 절단될 수 있게 해주는 연결성분(bridging element)을 나타내며, Z는 유전적으로 코드화 가능한 아미노산의 서열이다.
  3. 제2항에 있어서, Z에 인접한 Y가 MetㆍCysㆍTrpㆍArg 또는 Ly를 함유하거나, 이들 아미노산으로 이루어진 방법.
  4. 제2항에 있어서, Z에 인접한 Y가 아미노산 서열 Asp-Pro를 함유하거나, 이 서열크 이루어진 방법.
  5. 제1 내지 항 중 어느 한 항에 있어서, Z가 프로인슐린 또는 히루딘의 아미노산 서열을 나타내는 방법.
  6. 제1 내지 5항 중 어느 한 항에 있어서, 융합 단백질이 원심분리에 의해 가용성 단백질로부터 회수되는 방법.
  7. 제1 내지 6항 중 어느 한 항에 있어서, 숙주세포가 세균인 방법.
  8. 제7항에 있어서, 숙주세포가 이. 콜라이인 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860009990A 1985-11-27 1986-11-26 융합 단백질의 제조방법 KR950000300B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP3541856.7 1985-11-27
DE19853541856 DE3541856A1 (de) 1985-11-27 1985-11-27 Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens

Publications (2)

Publication Number Publication Date
KR870005098A true KR870005098A (ko) 1987-06-04
KR950000300B1 KR950000300B1 (ko) 1995-01-13

Family

ID=6286938

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860009990A KR950000300B1 (ko) 1985-11-27 1986-11-26 융합 단백질의 제조방법

Country Status (17)

Country Link
EP (3) EP0227938B1 (ko)
JP (1) JP2566933B2 (ko)
KR (1) KR950000300B1 (ko)
AT (2) ATE127841T1 (ko)
AU (1) AU595262B2 (ko)
CA (1) CA1341203C (ko)
DE (4) DE3541856A1 (ko)
DK (2) DK172064B1 (ko)
ES (3) ES2077747T3 (ko)
FI (1) FI93471C (ko)
GR (1) GR3005042T3 (ko)
HU (1) HU203579B (ko)
IE (1) IE59488B1 (ko)
IL (1) IL80755A0 (ko)
NO (1) NO176481C (ko)
PT (1) PT83813B (ko)
ZA (1) ZA868943B (ko)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3125021A (en) * 1955-11-14 1964-03-17 Smooth
EP0168342B1 (de) * 1984-06-14 1991-07-03 Ciba-Geigy Ag Verfahren zur Herstellung von Thrombin-Inhibitoren
DE3712985A1 (de) * 1987-04-16 1988-11-03 Hoechst Ag Bifunktionelle proteine
DE3545568A1 (de) * 1985-12-21 1987-07-16 Hoechst Ag Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung
DE3819079A1 (de) * 1988-06-04 1989-12-07 Hoechst Ag Hirudin-derivate mit verzoegerter wirkung
DE3835815A1 (de) * 1988-10-21 1990-04-26 Hoechst Ag Neue isohirudine
DE3844211A1 (de) * 1988-12-29 1990-07-05 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5179196A (en) * 1989-05-04 1993-01-12 Sri International Purification of proteins employing ctap-iii fusions
WO1991000912A1 (en) * 1989-07-07 1991-01-24 Massachusetts Institute Of Technology Production and use of hybrid protease inhibitors
CU22222A1 (es) * 1989-08-03 1995-01-31 Cigb Procedimiento para la expresion de proteinas heterologicas producidas de forma fusionada en escherichia coli, su uso, vectores de expresion y cepas recombinantes
GB8927722D0 (en) * 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
DE3942580A1 (de) * 1989-12-22 1991-06-27 Basf Ag Verfahren zur herstellung von hirudin
US5270181A (en) * 1991-02-06 1993-12-14 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
DE4140381A1 (de) * 1991-12-07 1993-06-09 Hoechst Ag, 6230 Frankfurt, De Neue synthetische isohirudine mit verbesserter stabilitaet
DE4404168A1 (de) * 1994-02-10 1995-08-17 Hoechst Ag Hirudinderivate und Verfahren zu deren Herstellung
ATE264871T1 (de) 1996-07-26 2004-05-15 Aventis Pharma Gmbh Insulinderivate mit erhöhter zinkbindung
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
DE19825447A1 (de) 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
DE10033195A1 (de) * 2000-07-07 2002-03-21 Aventis Pharma Gmbh Bifunktionale Fusionsproteine aus Hirudin und TAP
US7202059B2 (en) 2001-02-20 2007-04-10 Sanofi-Aventis Deutschland Gmbh Fusion proteins capable of being secreted into a fermentation medium
US7638618B2 (en) 2001-02-20 2009-12-29 Sanofi-Aventis Deutschland Gmbh Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
RS56632B1 (sr) 2008-10-17 2018-03-30 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
ES2855146T3 (es) 2009-11-13 2021-09-23 Sanofi Aventis Deutschland Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
HUE031181T2 (en) 2010-08-30 2017-06-28 Sanofi Aventis Deutschland Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN103917241A (zh) 2011-08-29 2014-07-09 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
JP6970615B2 (ja) 2014-12-12 2021-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリングラルギン／リキシセナチド固定比処方
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
KR20200080747A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법
KR20200080748A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985000817A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
DK108685A (da) * 1984-03-19 1985-09-20 Fujisawa Pharmaceutical Co Vaekstfaktor i
DE3586333T2 (de) * 1984-03-27 1992-12-10 Transgene Sa Expressionsvektoren fuer hirudin, transformierte zellen und verfahren zur herstellung von hirudin.
EP0158198A1 (en) * 1984-03-29 1985-10-16 Takeda Chemical Industries, Ltd. DNA and use thereof
DE3429430A1 (de) * 1984-08-10 1986-02-20 Hoechst Ag, 6230 Frankfurt Gentechnologisches verfahren zur herstellung von hirudin und mittel zur durchfuehrung dieses verfahrens
DE3526995A1 (de) * 1985-07-27 1987-02-05 Hoechst Ag Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung
CA1297003C (en) * 1985-09-20 1992-03-10 Jack H. Nunberg Composition and method for treating animals
US4865974A (en) * 1985-09-20 1989-09-12 Cetus Corporation Bacterial methionine N-terminal peptidase

Also Published As

Publication number Publication date
PT83813A (de) 1986-12-01
EP0227938B1 (de) 1992-04-15
NO176481C (no) 1995-04-12
EP0227938A3 (en) 1988-11-23
EP0464867A1 (de) 1992-01-08
NO176481B (no) 1995-01-02
ES2073081T3 (es) 1995-08-01
DK52292A (da) 1992-04-21
DE3684892D1 (de) 1992-05-21
AU6569386A (en) 1987-06-04
DK52292D0 (da) 1992-04-21
EP0468539B1 (de) 1995-09-13
PT83813B (pt) 1989-06-30
GR3005042T3 (ko) 1993-05-24
FI864798A0 (fi) 1986-11-25
NO864759D0 (no) 1986-11-26
EP0464867B1 (de) 1995-05-10
DE3650322D1 (de) 1995-06-14
ATE127841T1 (de) 1995-09-15
CA1341203C (en) 2001-03-13
ATE122397T1 (de) 1995-05-15
ES2077747T3 (es) 1995-12-01
IL80755A0 (en) 1987-02-27
EP0227938A2 (de) 1987-07-08
DK568586A (da) 1987-05-28
KR950000300B1 (ko) 1995-01-13
DE3650396D1 (de) 1995-10-19
FI93471C (fi) 1995-04-10
DK172064B1 (da) 1997-10-06
JP2566933B2 (ja) 1996-12-25
ZA868943B (en) 1987-07-29
ES2032378T3 (es) 1993-02-16
IE59488B1 (en) 1994-03-09
DE3541856A1 (de) 1987-06-04
HUT43642A (en) 1987-11-30
IE863119L (en) 1987-05-27
HU203579B (en) 1991-08-28
JPS62143696A (ja) 1987-06-26
FI93471B (fi) 1994-12-30
FI864798A (fi) 1987-05-28
DK172210B1 (da) 1998-01-05
EP0468539A1 (de) 1992-01-29
AU595262B2 (en) 1990-03-29
DK568586D0 (da) 1986-11-26

Similar Documents

Publication Publication Date Title
KR870005098A (ko) 융합 단백질의 제조방법
EP0722461A4 (en) EXPRESSION OF FUSION POLYPEPTIDES TRANSPORTED OUT OF CYTOPLASM WITHOUT HEAD SEQUENCE
DE69534381D1 (de) Hämatopoietisches fusionsprotein multivariantes il-3 enthaltend
KR950000301B1 (ko) 진핵 밸러스트 부분(ballast portion)을 갖는 융합 단백질의 제조방법
DE69637874D1 (de) C-C CHEMOKIN REZEPTOR 3: CKR-3 ODER Eos-L2
KR870001312A (ko) 융합 단백질의 제조방법
EP0068693A3 (en) Production of foot and mouth disease vaccine from microbially expressed antigens
KR870006188A (ko) 과립구 대식세포 콜로니 촉진 인자(gm-csf) 단백질의 제조방법
ATE342367T1 (de) Verwendung von fusionsproteinen, deren n- terminaler teil aus einem hirudinderivat besteht, zur herstellung rekombinanter proteine durch sekretion durch hefen
ES2120947T3 (es) Secuencias de adn, vectores y polipeptidos de fusion para incrementar la secrecion de polipeptidos deseados a partir de hongos filamentosos.
KR880012758A (ko) 폴리펩타이드의 유전공학적 제조방법
KR890013178A (ko) 인간의 콜로니 자극인자
KR880014102A (ko) 스트렙토마이세테스(Streptomycetes)에서 외래성 단백질을 제조하는 방법
DE3686036D1 (en) New fusion protein contg. small interleukin 2 ballast fragments
RU92004585A (ru) Промотор, днк-последовательность, вектор, клетки, способ экспрессии днк
GR3024625T3 (es) Calcium-regulated promoter
KR900702047A (ko) 재조합 pdgf와 그 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20011229

Year of fee payment: 8

LAPS Lapse due to unpaid annual fee